Screening of AZD5305 and other PARPi on a panel of larger cell lines indicated that, as treated with different sensitivity cells, a differential clustering was revealed, which suggested that in different genetic backgrounds, AZD5305 may be utilized as a unique tool to explore and refine selective PARP1-related activities in cancer cells, and the effects of targeting them (Illuzzi et al., 2021). The gene discussed is PARP1; the disease is cancer.